Biosimilar Battlefield: Celltrion Forecasts
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
601 Views
Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 2017
Daiichi Sankyo [DSK] (4568 JP) released Phase I data for DS-8201 at ESMO 2017 as follows: 32% overall response rate, 82% disease control rate. The...
279 Views
Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data
Chugai Pharmaceutical (4519 JP) announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi)...
344 Views
Chugai – Positive Data for Emicizumab from HAVEN 2
After Alecensa impressed in Phase III trials earlier this week, Chugai (4519 JP) had the added pleasure of seeing emicizumab do well in the second...
372 Views
Chugai Pharmaceutical: Update Ahead of Summer Data Releases
The excitement at Chugai Pharmaceutical (4519 JP) is palpable for all to see, and you quickly get the impression at any meeting that the company is...
226 Views